Map of US state actions related to COVID-19 vaccine infrastructure from April to December 2025. States are shaded to indicate action types: no action, strengthened, weakened, or both. The map includes notations like "text@0", "text@1", "text@2(1S/1W)", "text@3(2S/1W)", "text@4", and "text@5".

US state-level policy responses to shifting federal guidance varied widely in 2025, with most states acting to preserve #COVID19 vaccination access through standing orders, insurance coverage, or clinician authority.

ja.ma/4ckW8Fh

Screen shot of study title and authors

The most impactful clinical ILD study in ages! 🌟
True multidisciplinary collaboration driving progress 🫁
@rogerjlewis.bsky.social @ipfdoc.bsky.social

A Statistical Model for Lung Function Trajectory and Mortality in Patients with Fibrotic ILD

academic.oup.com/ajrccm/advan...
#OpenAccess

This is the face of a lunar scientist who has just been told that the #Artemis II crew saw SEVERAL impact flashes (the flashes when meteors hit the lunar surface) in real time 😃 🌓💥

JAMAevidence JAMA Guide to Statistics and Methods, video published April 2, 13 min, titled "Test-Negative Study Designs for Evaluating Vaccine..." with a play button.

JAMA Statistical Editor @rogerjlewis.bsky.social MD, PhD, and Natalie Dean, PhD, discuss the test-negative study design, highlighting its role in analyzing effectiveness and minimizing bias in observational studies.

🎧 Listen now: ja.ma/4tl3MF9

So, I mentioned this to a manager, who calmly told me "yeah, the corporate office does that to fool people. They won't fix that if we complain."

PS Yes, I know what they did wrong math-wise.

I stopped and stared at the price per ounce numbers for a few minutes trying to reproduce Kroger's / Ralph's math, especially since they are misleading in way that would make you buy a larger package that was actually more expensive per ounce.

JAMAevidence JAMA Guide to Statistics and Methods; March 5, 17 min; Platform Clinical Trials for the Efficient Evaluation of Multiple...; JAMAevidence JAMA Guide to...; Play Button.

JAMA Statistical Editor @rogerjlewis.bsky.social, MD, PhD, and Steve Webb, MBBS, MPH, PhD, discuss the key features of platform trials, including adaptive structures, shared control groups, and domain-based randomization.

🎧 Listen now: ja.ma/3Pk33oU

I wonder what decision process or discussion initially led to this course of action, let alone the decision to perpetuate it. It's difficult for me to picture it.

JAMA | Original Investigation: "Prediction of Bacteremia and Bacterial Meningitis Among Febrile Infants Aged 28 Days or Younger." Key points discuss accuracy of clinical prediction rules based on lab results to identify risk in young infants.

The updated PECARN rule reliably identified low-risk febrile infants, with no missed cases of bacterial meningitis, potentially reducing routine lumbar punctures.

bit.ly/3Zkwf1a

Among patients with acute ischemic #stroke due to non–large vessel occlusion, #tenecteplase administered 4.5 to 24 hours after symptom onset increased excellent outcomes but raised the risk of intracranial #hemorrhage. #ISC26

📽️ Watch the video & read the full study: bit.ly/4kgH1yQ

I do watch (and enjoy) it...

Opinion | No, I Won't Watch 'The Pitt' But you probably should

No, I Won't Watch 'The Pitt' www.medpagetoday.com/opinion/pres...

A JAMA article titled "Win Ratio Method for Hierarchical Composite Outcomes in Randomized Clinical Trials". Article discusses composite end points, win ratio, and time-to-event outcomes.

📊 JAMA Guide to Statistics and Methods: The win ratio is a statistical method for hierarchical composite outcomes, offering a patient-centered summary of treatment effects by prioritizing more important clinical events in clinical trials.

ja.ma/4qIidSJ

WHO removing Us Flag

An announcement from Noah Wyle and the CDC:

Mifepristone and the Future of FDA Drug Regulation On September 19, 2025, US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr and US Food and Drug Administration (FDA) Commissioner Martin Makary announced that HHS would be ...

jamanetwork.com/journals/jam...

Navigating Conflicting Vaccination Recommendations This Perspective discusses how clinicians can navigate conflicting vaccination recommendations following revisions from the Advisory Committee on Immunization Practices and US Centers for Disease Cont...

jamanetwork.com/journals/jam...

JAMAevidence presents 'JAMA Guide to Statistics and Methods.' Tipping Point Analysis: Assessing the Potential Impact. A play button indicates video content from JAMAevidence JAMA Guide to...

In this podcast, @rogerjlewis.bsky.social, MD, PhD, Senior Statistical Editor for JAMA, speaks with Kendra Sims, PhD, postdoctoral associate at @busph.bsky.social, about how tipping point analysis can help assess the robustness of study findings.

Listen now: ja.ma/49fpFi5

Some beautiful keepsakes nurses made for a dying patient's family at Harbor-UCLA.

I Left the CDC 100 Days Ago. My Worst Fears About the Agency Are Coming True "Things have not improved," writes Dr. Debra Houry. "They have worsened. And Congress has still failed to act."

“I did not resign to make a symbolic point. I resigned because staying silent would have made me complicit. I spoke up because the stakes for children, communities, and our preparedness are too high.” time.com/7338714/dr-d...

Supporting the Call for Evidence-Based Policy and Public Health Security — No Patient Left Behind

Here, here.

"Congress must now also exercise its oversight responsibilities to ensure repairs to FDAs current and future capabilities, infrastructure, human resources, and reputation begin as soon as possible."

Big deal coming from investors/companies.

www.nopatientleftbehind.org/evidence-bas...

Ohio State and Partners Secure Grant to Inform Future Vision of FDA Researchers at The Ohio State University Moritz College of Law and partner universities were recently awarded a grant from Arnold Ventures to support a multi-faceted research project, titled “A Princi...

Excited to work with @pzettler.bsky.social and @reshmagar.bsky.social on this new project supported by @arnoldventures.bsky.social with the goal of developing a principles-based approach to rebuilding and re-envisioning FDA.

moritzlaw.osu.edu/ohio-state-a...

thank you @drdebhoury.bsky.social !!

Our new kitten was discovered alone and outside by a kind soul at approximately four weeks of age (first measured weight was 395 g). She appears to be settling into the household nicely. Our labradoodle is (very gently) trying to ignore her.

Thanks on behalf of the entire SNAP team--happy to have contributed to #3!

Opinion | MAHA Threatens My Life. I Understand Its Appeal. The Trump administration has undermined the once bipartisan war on cancer and declined to approve a promising melanoma therapy.

In @nytopinion.nytimes.com

“Even as my own life is imperiled by the Trump administration’s actions, I understand the populist rage and institutional distrust that drive the Make America Healthy Again movement,” writes Sam Braslow, who has Stage IV melanoma.

Happy Veterans Day! This post is celebrating my mother's service as a WASP--Women Airforce Service Pilot--during WW II, flying P-52s, P-47s, etc. from the factory to bases for subsequent deployment. Flying newly built planes is risky; 38 of the 1074 women died, often due to mechanical failures.

📢 JAMA Senior Statistical Editor @rogerjlewis.bsky.social, MD, PhD, @jamaotolaryngology.com EIC Jay Piccirillo, MD, & @jamaotolaryngology.com Statistics Editor Dorina Kallogjeri, MD, MPH, will be speakers at the 2nd Annual Midwest Critical Appraisal Workshop.

See flyer for more details. ⬇️

On halloween there’s nothing spookier than a future without CDC

Love this quote! Much of clinical trial design at statistical rigor is aimed at preventing this.